SLC5A2 and Alzheimer disease: Furthermore, SGLT2 inhibitors have been shown to reduce hyperphosphorylated tau and Aβ accumulation while enhancing brain insulin signaling in a type 2 diabetes–AD mouse model (Sim et al. 2023).